Giuseppe S. Alvaro
Gründer bei Autifony Therapeutics Ltd.
Ursprung des Netzwerks ersten Grades von Giuseppe S. Alvaro
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Giuseppe S. Alvaro
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Tal Medical, Inc.
Tal Medical, Inc. Medical SpecialtiesHealth Technology Tal Medical, Inc. operates as a clinical stage medical device company. It develops novel, non contact, neuromodulatory devices for the treatment of psychiatric and neurological disorders. The firm focuses on the development of LFMS for the treatment of major depressive disorder and bipolar depression. The company was founded by Daphne Zohar, Steven Marc Paul, Andrew Miller, Eric Elenko and Nessan Bermingham in 2010 and is headquartered in Boston, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
University of Virginia | College/University | Doctorate Degree | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
IP GROUP PLC | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
University of Bristol | College/University | Doctorate Degree | |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
Lilly Research Laboratories
Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Parke-Davis Pharmaceutical Research, Inc. | Director/Board Member | ||
University of Lucknow | College/University | Doctorate Degree | |
St. Paul's Girls' School | College/University | Director/Board Member | |
KARA THER | Pharmaceuticals: Major | Director/Board Member | |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
Harvard Business School | College/University | Masters Business Admin | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Michigan Medical School | College/University | Corporate Officer/Principal | |
Verity BioConsulting LLC | Chief Executive Officer | ||
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member | |
PURETECH HEALTH PLC | Biotechnology | Chief Tech/Sci/R&D Officer | |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
SV Health Investors UK Ltd.
SV Health Investors UK Ltd. Financial ConglomeratesFinance Part of SV Health Investors LLP, SV Health Investors UK Ltd. is a company that provides investment services. The company is based in London, UK and was founded in 2004. | Financial Conglomerates | Director/Board Member | |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member | |
Ervaxx Ltd.
Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Pharmaceuticals: Major | Director/Board Member | |
IMMUNOVANT, INC. | Biotechnology | Director/Board Member | |
Alchemab Therapeutics Ltd.
Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Biotechnology | Director/Board Member | |
Zarodex Therapeutics Ltd.
Zarodex Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Mestag Therapeutics Ltd.
Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
Cybele Therapeutics Ltd.
Cybele Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | Miscellaneous Commercial Services | Director/Board Member | |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | Biotechnology | Chairman |
Statistik
International
Vereinigtes Königreich | 29 |
Vereinigte Staaten | 19 |
Dänemark | 4 |
Indien | 2 |
Sektoral
Health Technology | 32 |
Consumer Services | 8 |
Commercial Services | 6 |
Finance | 5 |
Health Services | 2 |
Operativ
Director/Board Member | 99 |
Corporate Officer/Principal | 28 |
Independent Dir/Board Member | 18 |
Chairman | 13 |
Undergraduate Degree | 8 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Elaine Jones | 37 |
Kate Bingham | 31 |
John Berriman | 24 |
Bobby G. Soni | 23 |
Atul Pande | 20 |
Allan J. Baxter | 9 |
Barbara Domayne-Hayman | 7 |
Charles H. Large | 4 |
Barbara Domayne Hayman | 3 |
- Börse
- Insiders
- Giuseppe S. Alvaro
- Unternehmensverbindungen